P&G sells Sure
This article was originally published in The Rose Sheet
Executive Summary
Innovative Brands has completed the acquisition of the Sure antiperspirant and deodorant brand from Procter & Gamble, the division of Najafi Companies reports Sept. 26. "We will focus investments to increase awareness, create excitement, and build successful marketing relationships for this brand," the firm says, noting the range "can appeal to both the male and female segments of the market because of its quality performance attributes and simple fragrances." The acquisition is in line with the company's strategy of purchasing consumer brands that no longer fit the strategic direction of larger corporations. In July, Innovative Brands acquired Pert hair care brand from P&G (1"The Rose Sheet" July 17, 2006, In Brief)...
You may also be interested in...
P&G sells Pert
Procter & Gamble has sold its PertPlus hair care brand to private equity firm Najafi Companies in order to focus on core brands Aussie,Head & Shoulders, Herbal Essences,Infusium 23 and Pantene, according to the company. Phoenix, Ariz.-based Najafi will assume ownership of the brand in the U.S., Canada, Puerto Rico and the Caribbean; however, P&G will retain the rights to Pert Plus in Asia and Latin America. Pert Plus will be part of Najafi's Innovative Brands division, which plans to "grow and sustain the brand for the long term," Najafi states. "There are tremendous opportunities for growth and product expansion," Innovative Brands adds...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.